Six courses of fluorouracil + epirubicin + cyclophosphamide (FEC100) versus three courses of FEC100 followed by three courses of docetaxel in women with localised, resectable, non-pretreated unilateral breast cancer.
Phase of Trial: Phase III
Latest Information Update: 01 Jul 2012
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
- Indications Early breast cancer
- Focus Therapeutic Use
- 01 Jul 2012 Eight-year follow-up results published in Oncologist.
- 05 Nov 2010 New trial record.
- 20 Dec 2006 Results published in the Journal of Clinical Oncloogy